NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $8.54 -0.09 (-1.04%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.37▼$8.7650-Day Range$6.05▼$9.7452-Week Range$3.14▼$13.70Volume575,774 shsAverage Volume725,988 shsMarket Capitalization$530.80 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fulcrum Therapeutics alerts: Email Address Fulcrum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.3% Upside$16.33 Price TargetShort InterestBearish13.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.48) to ($1.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 starsMedical Sector714th out of 910 stocksPharmaceutical Preparations Industry335th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Fulcrum Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.11% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 2.5 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Fulcrum Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for FULC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.48) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Fulcrum Therapeutics Stock (NASDAQ:FULC)Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FULC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Stock News HeadlinesAugust 29, 2024 | americanbankingnews.comFulcrum Therapeutics Target of Unusually High Options Trading (NASDAQ:FULC)August 28, 2024 | finance.yahoo.comOne Fulcrum Therapeutics Insider Raised Their Stake In The Previous YearSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 27, 2024 | entrepreneur.com3 High-Potential Biotech Stocks Under $10August 27, 2024 | globenewswire.comFulcrum Therapeutics to Participate in Upcoming September ConferencesAugust 27, 2024 | forbes.comScaling Up Without Selling Out: How Biotechs Can Preserve Culture During CommercializationAugust 23, 2024 | bizjournals.comThe Petri Dish: Abata lands big pharma funds; Broad’s new partnerAugust 23, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 19, 2024 | globenewswire.comFulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance OfficerAugust 13, 2024 | finance.yahoo.comAtavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business OfficerAugust 9, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2024 | investing.comFulcrum Therapeutics (FULC) Earnings Dates & ReportsAugust 6, 2024 | barrons.comFulcrum Therapeutics Inc.July 31, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024July 31, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024July 30, 2024 | markets.businessinsider.comFulcrum Therapeutics earnings: here's what Wall Street expectsJuly 30, 2024 | msn.comFulcrum Therapeutics Q2 2024 Earnings PreviewSee More Headlines Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$23.00 Low Stock Price Target$14.00 Potential Upside/Downside+91.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,330,000.00 Net Margins-3,470.05% Pretax Margin-24.79% Return on Equity-8.28% Return on Assets-7.61% Debt Debt-to-Equity RatioN/A Current Ratio22.07 Quick Ratio22.07 Sales & Book Value Annual Sales$81.63 million Price / Sales6.50 Cash FlowN/A Price / Cash FlowN/A Book Value$4.39 per share Price / Book1.95Miscellaneous Outstanding Shares62,154,000Free Float59,606,000Market Cap$530.80 million OptionableOptionable Beta2.23 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Alexander C. Sapir (Age 57)CEO, President & Director Comp: $961.26kMr. Alan A. Musso C.M.A. (Age 62)CPA, Chief Financial Officer Comp: $545.1kMr. Curtis G. Oltmans J.D. (Age 61)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $585.4kMr. Mel Hayes (Age 54)Executive Vice President of Patient Experience Comp: $631.5kDr. Bradley E. Bernstein M.D.Ph.D., FounderDr. Michael R. GreenFounderDr. Rudolf Jaenisch M.D.Ph.D., FounderDr. Tsun-Huei Lee M.D. (Age 60)Ph.D., Founder Dr. Danny ReinbergFounderMr. Gregory TourangeauController & Principal Accounting OfficerMore ExecutivesKey CompetitorsOrchard TherapeuticsNASDAQ:ORTXSangamo TherapeuticsNASDAQ:SGMObluebird bioNASDAQ:BLUEKezar Life SciencesNASDAQ:KZRVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 27,633 shares on 8/16/2024Ownership: 0.066%Susquehanna Portfolio Strategies LLCSold 87,558 shares on 8/15/2024Ownership: 0.131%The Manufacturers Life Insurance Company Bought 24,480 shares on 8/15/2024Ownership: 0.039%Caxton Associates LPBought 18,875 shares on 8/15/2024Ownership: 0.030%Profund Advisors LLCBought 10,921 shares on 8/14/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions FULC Stock Analysis - Frequently Asked Questions How have FULC shares performed this year? Fulcrum Therapeutics' stock was trading at $6.75 on January 1st, 2024. Since then, FULC shares have increased by 26.5% and is now trading at $8.54. View the best growth stocks for 2024 here. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Wednesday, July, 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.93. The business earned $80 million during the quarter, compared to analyst estimates of $80 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 8.28% and a negative net margin of 3,470.05%. When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' top institutional investors include Dimensional Fund Advisors LP (2.38%), Simplify Asset Management Inc. (1.09%), Assenagon Asset Management S.A. (0.80%) and Marshall Wace LLP (0.54%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV) and Xeris Biopharma (XERS). This page (NASDAQ:FULC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
